Revalia Bio
PrivateLast Round
Grant
Dec 5, 2025
Total Funding Raised
$46.2M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Revalia Bio operates in Healthcare & Life Sciences and is based in New Haven, Connecticut. Its latest recorded funding round was a Grant round in December 2025.
Revalia Bio is a biotechnology company that provides a 'Human Data Trials' platform, enabling drug developers to test therapeutics on functional human organs obtained from deceased donors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Revalia Bio Comparables
Compare Revalia Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bexorg | 83% | |
| AnaBios | 78% | |
| Hesperos Inc. | 74% |
For institutional investors. Book with your work email.
Revalia Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 5, 2025 | ||||
| Seed | Sep 4, 2025 | ||||
| Pre Seed | Oct 17, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Revalia Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Connecticut Innovations | Seed, Pre Seed |
| Sierra Ventures | Seed |
| America's Frontier Fund | Seed |
| AFF | Seed |
| Pamir Ventures | Seed |
| BoxOne Ventures | Seed |
| ARPA-H | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 35% MoM.
- Aug 16, 2026
Grew 23% QoQ, from 30 to 37 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- expands_offices_inOct 5, 2026
On Oct 5th '26, Revalia Bio, Inc. plans to expand its New Haven workforce as pharmaceutical demand for human-organ testing grows and its technology advances.
- hiresSep 16, 2026
Revalia Bio, Inc. names Casimir “Caz” Starsiak III president and CEO in Connecticut, effective Sep 1st '26, to lead commercial expansion, pharmaceutical partnerships and operations scaling.
For institutional investors. Book with your work email.
Revalia Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Revalia Bio's valuation, stock price, and market status.
Is Revalia Bio a public or private company?
Revalia Bio is a private company.
What is the current stock price of Revalia Bio?
Revalia Bio is a private company, so its shares have no public market price. Caplight tracks Revalia Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Revalia Bio worth (valuation)?
Valuation information for Revalia Bio is not publicly available.
Can I buy Revalia Bio stock?
Revalia Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Revalia Bio's last funding round?
Revalia Bio's most recent funding round was Grant on December 5, 2025.
Who are the main investors in Revalia Bio?
Key investors in Revalia Bio include Sierra Ventures, America's Frontier Fund, AFF, ARPA-H.
Will Revalia Bio IPO soon?
No public IPO plans have been announced for Revalia Bio.
How can I track Revalia Bio secondary market activity?
Caplight tracks bids, offers, and trades in Revalia Bio's shares on secondary markets.